Skip to main content
Premium Trial:

Request an Annual Quote

Mayo Clinic Coronavirus Assay Gets Emergency Use Authorization

NEW YORK — The US Food and Drug Administration on Monday granted Emergency Use Authorization for the Mayo Clinic's PCR-based SARS-CoV-2 diagnostic assay.

According to the FDA, the SARS-CoV-2 Molecular Detection Assay is designed to detect RNA from the virus' nucleocapsid and ORF1ab genes in upper and lower respiratory specimens including nasopharyngeal swabs, throat swabs, nasal swabs, sputum, and tracheal secretions.

RNA is isolated using BioMérieux's easyMAG and EMAG extraction instruments, and the test runs on Roche's LightCycler 480 version 1.5.1.62.

Assay testing is limited to the Mayo Clinic's CLIA-certified lab, the FDA said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.